| pubmed-article:18405753 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18405753 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:18405753 | lifeskim:mentions | umls-concept:C0138741 | lld:lifeskim |
| pubmed-article:18405753 | lifeskim:mentions | umls-concept:C0194810 | lld:lifeskim |
| pubmed-article:18405753 | lifeskim:mentions | umls-concept:C0279025 | lld:lifeskim |
| pubmed-article:18405753 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:18405753 | lifeskim:mentions | umls-concept:C0205421 | lld:lifeskim |
| pubmed-article:18405753 | pubmed:issue | 5 Suppl | lld:pubmed |
| pubmed-article:18405753 | pubmed:dateCreated | 2008-4-14 | lld:pubmed |
| pubmed-article:18405753 | pubmed:abstractText | Hormonal therapy (HT) is the current mainstay of systemic treatment for prostate specific antigen (PSA) only recurrence (PSAR), however, there is virtually no published literature comparing HT to observation in the clinical setting. The goal of this study was to examine the Department of Defense Center for Prostate Disease Research observational database to compare clinical outcomes in men who experienced PSAR after radical prostatectomy by early versus delayed use of HT and by a risk stratified approach. | lld:pubmed |
| pubmed-article:18405753 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405753 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405753 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18405753 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18405753 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:18405753 | pubmed:month | May | lld:pubmed |
| pubmed-article:18405753 | pubmed:issn | 1527-3792 | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:MoulJudd WJW | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:McLeodDavid... | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:DonahueTimoth... | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:HernandezJavi... | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:WuHongyuH | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:SunLeonL | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:AmlingChristo... | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:KusudaLeoL | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:ChungAndrewA | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:SextonWadeW | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:SoderdahlDoug... | lld:pubmed |
| pubmed-article:18405753 | pubmed:author | pubmed-author:O'ReillyKeith... | lld:pubmed |
| pubmed-article:18405753 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18405753 | pubmed:volume | 179 | lld:pubmed |
| pubmed-article:18405753 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18405753 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18405753 | pubmed:pagination | S53-9 | lld:pubmed |
| pubmed-article:18405753 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18405753 | pubmed:articleTitle | Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. | lld:pubmed |
| pubmed-article:18405753 | pubmed:affiliation | Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20852, USA. jmoul@cpdr.org | lld:pubmed |
| pubmed-article:18405753 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18405753 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18405753 | lld:pubmed |
